Meeting
2024 ASCO Gastrointestinal Cancers Symposium
An ARCAD database nomogram for prognostic prediction of treatment refractory metastatic colorectal cancer.
Authors
Eiji Oki
Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University Hospital, Fukuoka, Japan
Eiji Oki , Hideaki Bando , Kentaro Yamazaki , Toshihiro Misumi , Yuriko Takeda , Motoko Suzuki , Masashi Wakabayashi , Axel Grothey , Robert J. Mayer , Jin Li , Thierry Andre , Qian Shi , Aimery De Gramont , Takayuki Yoshino
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Colorectal Cancer,Anal Cancer
Sub Track
Therapeutics
Citation
J Clin Oncol 42, 2024 (suppl 3; abstr 107)
DOI
10.1200/JCO.2024.42.3_suppl.107
Abstract #
107
Poster Bd #
G11
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Prognostic factors of patients (pts) with salvage-line metastatic colorectal cancer (mCRC).
First Author: Hideaki Bando
Poster
2022 ASCO Annual Meeting
Codon-specific KRAS mutations predict overall survival benefit of trifluridine/tipiracil in metastatic colorectal cancer.
First Author: Joris van de Haar
Poster
2019 Gastrointestinal Cancers Symposium
Blood-based biomarkers in metastatic colorectal cancer patients treated with FOLFIRI plus regorafenib or placebo: Results from LCCC1029.
First Author: Yingmiao Liu
Poster
2018 Gastrointestinal Cancers Symposium
Prognostic value of neutrophil-to-lymphocyte ratio (NLR) on overall survival (OS), progression free survival (PFS) and disease control rate (DCR) in patients with metastatic colorectal cancer (mCRC) from the RECOURSE study.
First Author: Guillem Argiles